Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

CACICOL®, the new therapeutic approach to the management of persistent epithelial defects and neurotrophic keratopathy

Poster Details

First Author: A.Hervas SPAIN

Co Author(s):    S. Garcia-Delpech   R. Diaz Cespedes   P. Udaondo   E. Sanz Marco   D. Salom   A. Cisneros Lanuza     

Abstract Details


Neurotrophic keratopathy (NK) is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, possibly leading to perforation. We aimed to assess the efficacy of the so-called “ReGeneraTing Agents”(RGTA®), CACICOL®, mimicking heparan sulfates, for the management of NK and Persistent Epithelial Defects (PED).


The study was done at universitary Hospital La Fe of valencia and Hospital of Manises, Valencia


We carried out an uncontrolled, prospective, single-centre clinical study on five patients (five eyes), between 48 and 65 years old, with chronic corneal NK and PED of different etiology, despite the use of hypoosmolar, preservative-free artificial tears and topical anti-inflamatory drugs, for at least 3 months. All patients were treated with CACICOL®, at a dose regimen of one daily drop every 2 days for 1 to 3 weeks. Evolution and follow-up during treatment were evaluated by slit-lamp examination, photograp


All patients displayed complete corneal healing. Total re-epithelization occurring after a mean period of 4.6 weeks within a period of two to twelve weeks. Mean ulcer area decreased significantly, from 12.17% to 7.49% (P=0.049) in the first week, and 12.17 to 1.93% (P=0.008) at one month. At the end of the study, none of the patients displayed significant improvement in visual acuity. There were no systemic or local side effects of treatment.


CACICOL® seems to be a potentially useful, alternative, non invasive therapeutic approach in neurotrophic keratopathy and Persistent Epithelial Defects management. However, randomized studies are necessary.

Financial Disclosure:


Back to Poster listing